-
EMA provides recommendations on compassionate use of remdesivir for COVID-19
EMA provides recommendations on compassionate use of remdesivir for COVID-19
-
EMA provides recommendations on compassionate use of remdesivir for COVID-19
EMA provides recommendations on compassionate use of remdesivir for COVID-19
EMA’s human medicines committee (CHMP) has given recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease (COVID-19) in compassionate use programmes in the European Union.
-
Update on treatments and vaccines against COVID-19 under development
Update on treatments and vaccines against COVID-19 under development
-
Update on treatments and vaccines against COVID-19 under development
Update on treatments and vaccines against COVID-19 under development
Supporting the rapid development and approval of effective and safe treatments for and vaccines against COVID-19 is EMA’s top priority. The Agency provides an update on therapeutics and vaccines under development against the disease.
-
The future of regulatory science in the EU
The future of regulatory science in the EU
-
The future of regulatory science in the EU
The future of regulatory science in the EU
EMA has published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.
-
COVID-19: latest updates
COVID-19: latest updates
-
COVID-19: latest updates
COVID-19: latest updates
Keep up to date with the latest information from EMA on the COVID-19 pandemic.
